A Case of Severe Multisystem Inflammatory Syndrome in Children (MIS-C) Treated with Multiple Biologics

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Medication</td><td class="align_center">Date started</td><td class="align_center">Date ended</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">IVIG</td><td class="align_center">05/16/2021</td><td class="align_center">05/17/2021</td></tr><tr><td class="align_left">Anakinra</td><td class="align_center">05/16/2021</td><td class="align_center">06/23/2021</td></tr><tr><td class="align_left">Infliximab</td><td class="align_center">05/19/2021</td><td class="align_center">05/20/2021</td></tr><tr><td class="align_left">Tocilizumab</td><td class="align_center">05/18/2021</td><td class="align_center">05/19/2021</td></tr><tr><td class="align_left">Ruxolitinib</td><td class="align_center">05/20/2021</td><td class="align_center">06/07/2021</td></tr><tr><td class="align_left">SoluMEDROL</td><td class="align_center">05/16/2021</td><td class="align_center">06/25/2021</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Timeline and duration of anti-inflammatory drugs.</div>

Case Reports in Rheumatology

tab2

Table 2

Table 2: A Case of Severe Multisystem Inflammatory Syndrome in Children (MIS-C) Treated with Multiple Biologics 